Juno Therapeutics, Inc. v. Kite Pharma, Inc.

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent

Question(s) Presented

“Section 112(a) of Title 35, United States Code, requires that a patent include a ‘specification,’ which ‘shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.’”

“The question presented is:”

“Is the adequacy of the ‘written description of the invention’ to be measured by the statutory standard of ‘in such full, clear, concise, and exact terms as to enable any person skilled in the art to make and use the same,’ or is it to be evaluated under the Federal Circuit’s test, which demands that the ‘written description of the invention’ demonstrate the inventor’s ‘possession’ of ‘the full scope of the claimed invention,’ including all ‘known and unknown’ variations of each component?”

Date
Proceedings and Orders
March 7, 2022
Application (21A461) granted by The Chief Justice extending the time to file until June 13, 2022.
June 29, 2022
Motion to extend the time to file a response is granted and the time is extended to and including August 24, 2022.
September 7, 2022
DISTRIBUTED for Conference of 9/28/2022.
October 3, 2022
DISTRIBUTED for Conference of 10/7/2022.
October 11, 2022
DISTRIBUTED for Conference of 10/14/2022.
October 24, 2022
DISTRIBUTED for Conference of 10/28/2022.
October 31, 2022
DISTRIBUTED for Conference of 11/4/2022.
November 7, 2022
Petition DENIED.
December 7, 2022
DISTRIBUTED for Conference of 1/6/2023.
January 9, 2023
Rehearing DENIED.